Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/112712
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations
Author: Thakkar, V.
Patterson, K.
Stevens, W.
Wilson, M.
Roddy, J.
Sahhar, J.
Proudman, S.
Hissaria, P.
Nikpour, M.
Citation: Clinical Rheumatology, 2018; 37(6):1563-1571
Publisher: Springer London
Issue Date: 2018
ISSN: 0770-3198
1434-9949
Statement of
Responsibility: 
Vivek Thakkar, Karen A. Patterson, Wendy Stevens, Michelle Wilson, Janet Roddy, Joanne Sahhar, Susanna Proudman, Pravin Hissaria, Mandana Nikpour
Abstract: Studies suggest elevated serum intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) levels may be markers of pulmonary arterial hypertension in systemic sclerosis (SSc-PAH). We sought to evaluate whether ICAM-1 and VCAM-1 levels are useful screening biomarkers for incident SSc-PAH. In this cross-sectional study, four groups were selected from the Australian Scleroderma Cohort Study: group 1 (n = 15) had definite PAH; group 2 (n = 19) had interstitial lung disease (ILD); group 3 (n = 30) were SSc-controls; and group 4 (n = 34) were healthy controls. Serum ICAM-1 and VCAM-1 levels were measured using the Millipore Milliplex MAP Human 2-Plex Panel. There were no differences in ICAM-1 levels in the PAH versus ILD group (263.0 ± 85.4 vs 380.4 ± 168.3 ng/mL, p = 0.136), SSc-controls (263.0 ± 85.4 vs 253.1 ± 98.0 ng/mL, p = 1.00), or healthy controls (263.0 ± 85.4 vs 201.8 ± 57.2 ng/mL, p = 0.093). Similarly, there were no differences in VCAM-1 level in PAH versus ILD groups (1476.2 ± 434.9 vs 1424.8 ± 527.6 ng/mL, p = 1.00) and SSc-controls (1476.2 ± 434.9 vs 1409.5 ± 341.1 ng/mL, p = 1.00). SSc subjects had significantly higher levels of ICAM-1 (297.4 ± 134.0 vs 201.8 ± 57.2 ng/mL, p < 0.0001) and VCAM-1 compared to healthy controls (1432.7 ± 427.4 vs 1125.6 ± 273.4 ng/mL, p < 0.0001). Neither ICAM-1 nor VCAM-1 is a specific screening biomarker of SSc-PAH. Instead, increased levels of these adhesion molecules in SSc, irrespective of pulmonary complications, suggest that they may play a role in SSc pathogenesis.
Keywords: Biomarker; Intercellular adhesion molecule-1 (ICAM-1); Pulmonary arterial hypertension; Screening; Systemic sclerosis; Vascular cell adhesion molecule-1 (VCAM-1)
Description: Published online: 23 April 2018
Rights: © International League of Associations for Rheumatology (ILAR) 2018
RMID: 0030086269
DOI: 10.1007/s10067-018-4081-7
Grant ID: http://purl.org/au-research/grants/nhmrc/1126370
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.